- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01147484
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197)
August 3, 2023 updated by: NCIC Clinical Trials Group
A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer
The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor negative.
Study Overview
Detailed Description
This research is being done because there is no treatment that will cure this type of cancer.
Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- BCCA - Cancer Centre for the Southern Interior
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA - Vancouver Cancer Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- QEII Health Sciences Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Health Research Institute - General Division
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Hopital Charles LeMoyne
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of invasive breast cancer, that is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative.
- Formalin fixed paraffin embedded tissue available for central pathology review and translational studies. Patients entered on the second stage of accrual must have an accessible tumour lesion for biopsy.
- Advanced or recurrent/ metastatic disease incurable with standard therapies.
- Clinically and/or radiologically documented measurable disease. At least one site of disease must be unidimensionally measurable.
- ECOG performance of 0, 1 or 2.
- Age ≥ 18 years of age.
- Previous Therapy: Any treatment-related major organ toxicities must be recovered to ≤ grade 1.
- Patients may have received adjuvant chemotherapy and/or one prior line of chemotherapy in the recurrent/metastatic setting. A minimum of 21 days since the last dose of chemotherapy must have elapsed prior to registration.
- No prior therapy with a c-Met inhibitor or angiogenesis inhibitor. Other targeted agents are permissible provided a minimum of 21 days has elapsed since last day of targeted therapy and registration.
- Prior radiation therapy permitted provided the patient has recovered from acute toxic effects of the radiation therapy prior to registration, and at least 21 days have elapsed from the day of the last fraction of radiation to the date of registration. Exceptions may be made for non-myelosuppressive radiation to peripheral areas.
- Previous surgery permitted provided wound healing has occurred and at least 14 days have elapsed if surgery was major.
- Granulocytes (AGC) ≥ 1.5 x 109/L; Platelets ≥ 100 x 109/L
- Serum creatinine ≤ 1.2 x UNL; Total bilirubin ≤ 1.2 x UNL; ALT and AST ≤ 2 x UNL
- Women must be post menopausal, surgically sterile or use a reliable form of contraception while on study and for 90 days after discontinuing therapy. Women of childbearing potential must have a pregnancy test taken and proven negative within 7 days prior to registration and must not be lactating.
- Patients who require oral anticoagulants (coumadin, warfarin) are eligible
- Patient consent must be obtained according to local Institutional and/or University Human Experimentation Committee requirements.
- Protocol treatment must begin within 7 working days of patient registration.
Exclusion Criteria:
- History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years.
- Resting BP consistently higher than systolic > 150 mmHg and/or diastolic > 100 mmHg (in the presence or absence of a stable dose of anti-hypertensive medication) or poorly controlled hypertension, history of labile hypertension or poor compliance with anti-hypertensive medication.
- Appreciable cavitating or actively bleeding lesions.
- Untreated brain or meningeal metastases. (Patients with neurologically stable and treated brain metastases who have discontinued corticosteroids at least two weeks prior to study registration and have no evidence of cavitation or hemorrhage are eligible).
- Untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction. Patients with a significant cardiac history (even if controlled) or prior anthracycline exposure are required to have an LVEF > 50%.
- GI tract disease resulting in an inability to absorb oral medication.
- Active or uncontrolled infections, or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol.
- Known hypersensitivity to the study drugs or their components.
- Potent CYP3A4 inhibitors/inducers (e.g. ketoconazole, carbamazepine) must be discontinued at least 7 days prior to Day 1, Cycle 1.
- Treatment, concurrent or within 3 weeks prior to registration, with other investigational drugs or anti-cancer therapy.
- Proliferative diabetic retinopathy, retinal arteritis or hemorrhage.
- History of pulmonary embolus or a deep vein thrombosis diagnosed and/or treated within 6 months prior to registration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Foretinib
|
foretinib, at a continuous oral daily dose of 60 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response and early progression rate
Time Frame: Every 8 weeks
|
All patients will be assessed for response at the end of every second cycle (every 8 weeks).
Response and progression will be evaluated using RECIST 1.1.
|
Every 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events as a Measure of Safety and Tolerability
Time Frame: every 4 weeks
|
All patients will be assessed for toxicity at the end of every cycle (every 4 weeks).
Adverse events will be graded using CTCAE V4.0.
|
every 4 weeks
|
Relationship between response and biomarkers
Time Frame: 2 years (end of study)
|
Archival tissue will be collected on all patients.
Pre-treatment fresh tissue biopsies CTC's will be collected on all patients entered in the second stage of accrual.
Translational research studies will be done as described in protocol section 17.0.
|
2 years (end of study)
|
Biomarkers in Tumour cells
Time Frame: 2 years (end of study)
|
Archival tissue will be collected on all patients.
Pre-treatment fresh tissue biopsies CTC's will be collected on all patients entered in the second stage of accrual.
Translational research studies will be done as described in protocol section 17.0.
|
2 years (end of study)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Sasha Lupichuk, Tom Baker Cancer Centre, Calgary AB
- Study Chair: Daniel Rayson, QEII HSC - Nova Scotia Cancer Centre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 2, 2010
Primary Completion (Actual)
December 14, 2014
Study Completion (Actual)
February 13, 2015
Study Registration Dates
First Submitted
May 27, 2010
First Submitted That Met QC Criteria
June 18, 2010
First Posted (Estimated)
June 22, 2010
Study Record Updates
Last Update Posted (Actual)
August 4, 2023
Last Update Submitted That Met QC Criteria
August 3, 2023
Last Verified
April 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- I197
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Breast Cancer
-
Nanogen Pharmaceutical Biotechnology Joint Stock...Vietstar Biomedical Research; MedProve IncCompletedBreast Cancer Recurrent | Breast Cancer Female | Breast Cancer MetastaticVietnam
-
Nanogen Pharmaceutical Biotechnology Joint Stock...Vietstar Biomedical Research; MedProve IncCompletedBreast Cancer Recurrent | Breast Cancer Female | Breast Cancer MetastaticVietnam
-
Virginia Commonwealth UniversityEli Lilly and Company; BayerTerminatedBreast Cancer | Metastatic Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaTerminatedRecurrent Breast Cancer | Metastastic Breast CancerUnited States
-
Korean Breast Cancer Study GroupUnknownMetastatic Breast Cancer | Recurrent Breast CancerKorea, Republic of
-
Stanford UniversityNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Spexis AGTerminatedMetastatic Breast Cancer | Locally Recurrent Breast CancerSpain, Belgium, United States, United Kingdom, Korea, Republic of, Taiwan, Italy, Russian Federation, Czechia, France, Brazil, Argentina, Ukraine
-
Asan Medical CenterCompletedStage IV Breast Cancer | Recurrent Breast CancerKorea, Republic of
-
Ontario Clinical Oncology Group (OCOG)Canadian Breast Cancer Research Alliance; Ontario Cancer Research NetworkCompletedMetastatic Breast Cancer | Recurrent Breast CancerCanada
Clinical Trials on Foretinib
-
GlaxoSmithKlineCompletedCarcinoma, Renal CellUnited States
-
GlaxoSmithKlineCompletedCarcinoma, HepatocellularTaiwan, Thailand, Hong Kong
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedNeoplasms, Head and NeckUnited States
-
NCIC Clinical Trials GroupGlaxoSmithKlineCompleted
-
GlaxoSmithKlineWithdrawn
-
NCIC Clinical Trials GroupGlaxoSmithKlineCompleted